Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.64 |
| ▸ | HTR2C | P28335 | 9/20 | 0.64 |
| ▸ | HTR2B | P41595 | 6/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.64 |
| ▸ | KMO | O15229 | 9/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946400 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL5050630 | 0.83 | HTR2A (0.53) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL5636335 | 0.83 | HTR2A (0.53) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL27645810 | 0.81 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL5843607 | 0.79 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL4950686 | 0.79 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069278 | 0.79 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069280 | 0.79 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL5787393 | 0.79 | KMO (0.47) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL6088764 | 0.78 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268131-B2 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2007-09-11 | — | — | US | disclosed |
| US-6989445-B2 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-01-24 | — | — | US | disclosed |
| US-20050277636-A1 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2005-12-15 | — | — | US | disclosed |
| WO-2005058911-A2 | SUBSTITUTED [1,4]OXAZINO[2,3-G]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050130960-A1 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277636-A1 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGS1, PTGIR | HTR2A 881/4885HTR2C 477/4885HTR2B 1198/4885 |
| US-20050130960-A1 | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGS1, PTGIR | HTR2A 881/4885HTR2C 477/4885HTR2B 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.